Janus kinase inhibitor market

Janus kinase (Jak) is a family of non-tyrosine receptor kinases, which play a major role in cytokine signaling. Binding of cytokines (ligand) to receptor results in receptor dimerization and ultimately activates Jak-mediated phosphorylation of the receptor. Jak phosphorylates STAT (Signal Transducer and Activator of Transcription proteins) and STAT dimer carries out the transcription of genes which are critical for signal cascade involved in inflammatory and immune response. Therefore, Janus kinase is used as a target in treatment of autoimmune disorders such as rheumatoid arthritis.

Janus Kinase Inhibitor Market Drivers

Jak inhibitors are increasingly preferred for industrial research due to their critical role in immune response signaling. For instance, in June 2018, Eli Lilly and Company announced approval from the U.S. Food and Drug Administration (FDA) for OLUMIANT (baricitinib) — an oral medication for rheumatoid arthritis in adults. Approval was granted for use of baricitinib in combination with methotrexate (MTX) or other disease-modifying antirheumatic drugs (DMARDs) or as monotherapy. The drug inhibits activation of Jak1/2 (Janus kinase 1 and 2) and decreases the production of inflammatory cytokines, thereby inhibiting inflammatory response. Therefore, increasing launch of new drugs is expected to fuel the global janus kinase inhibitor market growth over the forecast period.

Psoriatic arthritis is a form of arthritis, which is characterized by red patches of skin with silvery scales. Tofacitinib is a janus kinase inhibitor, which modulates cytokines that are required for signaling of inflammatory and immune response. Inclusion of new treatment options is expected to boost the global janus kinase inhibitor market growth over the forecast period. For instance, in December 2017, Pfizer Inc. received approval from the U.S. FDA for XELJANZ (TOFACITINIB) for treatment of adult patients suffering from psoriatic arthritis (PsA).

Furthermore, key manufacturers and research organizations are focused in research and development of new janus kinase inhibitor drugs. For instance, M.D. Anderson Cancer Center, in collaboration with Incyte Corporation, conducted phase -2 clinical trials (study completed in March 2017) to check effect of ruxolitinib in controlling advanced hematological malignancies.  Ruxolitinib is an inhibitor of Jak 1 and Jak2 kinases and arrests growth of transformed cells. Therefore, active research and development of new janus kinase inhibitor drugs is expected to fuel the global janus kinase inhibitor market growth over the forecast period.

Janus Kinase Inhibitor Market Regional Analysis

The Janus kinase pathway mediates intracellular signaling of over sixty cytokines. Dysregulation of cytokines causes systemic lupus erythematosus (SLE) -- an autoimmune disorder and chronic disease, which is characterized by inflammation of connective tissues such as cartilage and blood vessel lining. According to National Center for Biotechnology Information (NCBI), the highest prevalence and incidence of SLE was in recorded in North America (23.2/100 000 person) during the period August 2013- September 2016. Therefore, high prevalence of SLE is expected to boost North America janus kinase inhibitor market growth over the forecast period.

Increasing research and development projects for launch of new drugs is expected to fuel Asia Pacific janus kinase inhibitor market growth over the forecast period. For instance, Astellas Pharma Inc. — a Japan-based pharmaceutical company — conducted Phase-3 clinical trial (study completed in November 2017) of drug Peficitinib for treatment of Rheumatoid arthritis. The study was conducted to check the superiority of Peficitinib alone and in combination with disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis who did not show sufficient response to DMARDs. Peficitinib is an inhibitor of Jak 1 and Jak that inhibits Interleukin 2 dependent T cell proliferation and STAT5 phosphorylation. These factors are expected to support global janus kinase inhibitor market growth over the forecast period.

Janus Kinase Inhibitor Market Restraints

Regulatory challenges in launch of Janus kinase inhibitors is expected to hinder the market growth. For instance, in April 2017 the U.S. FDA requested Eli Lilly & Company to provide additional clinical data for the dosing of drug Olumiant to characterize safety concerns. Later in April 2018, the FDA denied company the approval for 4mg once daily dose of Olumiant due to safety concerns regarding arterial and venous thrombosis.    

Janus Kinase Inhibitor Market Key Players

Some of the key players operating in the global Janus kinase inhibitor market include, Eli Lilly and Company, Astellas Pharma Inc., Pfizer Inc.,  Baxter International Inc., Novartis International AG, Gilead Sciences Inc., Sierra Oncology, Inc., CTI BioPharma Corp., and Incyte Corporation.

Janus Kinase Inhibitor Market Taxonomy

The global janus kinase inhibitor market is segmented on the basis of drugs, indication, distribution channel and regions. 

By Drugs

• Baricitinib
• Tofacitinib
• Ruxolitinib
• Pipeline drugs
  • Peficitinib

By Indication

• Rheumatoid arthritis
• Psoriatic arthritis
• Systemic lupus erythematosus
• Others

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa